Should pharmacies offer private menopause services?

Is there enough demand?

Yes, and it is still rising. NHSBSA's annual HRT statistics, published on 23 October 2025, show 14.7 million HRT items dispensed in England in 2024/25, an 11% increase on 2023/24. The number of identified patients rose 6.4% to 2.8 million. The most prescribed product was estradiol 0.06% gel at 1.3 million items, up 13%. The HRT prescription prepayment certificate was used for 21% of items, nearly seven percentage points more than the year before.

Those are NHS figures; they do not count private supply. They also show where private demand sits. NHSBSA found the least deprived areas had more than twice as many identified HRT patients as the most deprived. The women most likely to seek and pay for menopause care are already the ones most likely to be on HRT. They are also the ones most likely to be frustrated by a wait to review it.

Policy is pushing the same way. On 23 October 2025 the government announced that menopause questions and support would be built into the NHS Health Check for adults aged 40 to 74, reaching nearly five million women. It cited 400,000 women becoming menopausal each year and fewer than one in ten feeling adequately informed. On 4 March 2026 it launched menopause action plans, asking employers with 250 or more staff to publish the steps they take from April 2026. It noted that one in ten women who worked through menopause had left a job because of symptoms. On 14 April 2026 the renewed Women's Health Strategy named menopause as a priority pathway. Every one of those measures identifies women with symptoms and sends them looking for someone to see.

Can a pharmacist prescribe HRT?

Yes. HRT products are prescription-only medicines under the Human Medicines Regulations 2012. A pharmacist independent prescriber may prescribe any POM within their competence, other than the controlled-drug exceptions that do not apply here. Estradiol, progesterone and combined products are not controlled drugs. Testosterone is, at Schedule 4, and NICE guideline NG23 treats its use for low sexual desire after the menopause as off-label; see our note on testosterone as a controlled drug.

Competence is the real test. The GPhC's In practice guidance for pharmacist prescribers was updated in April 2025. It expects prescribers to work within their scope, to base decisions on an adequate assessment, and to decide what monitoring follows each prescribing decision. The GMC's prescribing guidance sets the same expectations for doctors, including a review of ongoing treatment in paragraphs 92 to 96. A prescriber who has done a menopause-specific course, has access to the woman's history and has a plan for the three-month review meets that bar. One who has not should not be running the clinic yet.

Supply of prescribers is about to change. From September 2026 every newly registered pharmacist will qualify as an independent prescriber on registration. NHS England's Pathfinder programme tested community pharmacy prescribing across 164 sites and 33,000 consultations and closed on 31 December 2025. The University of Manchester's review on 20 January 2026 found GP supervision funding inadequate. Private services are where many of those new prescribers will get their first structured caseload. Our guide to becoming a pharmacist independent prescriber covers the routes.

Do you need an independent prescriber?

For anything beyond the pharmacy counter, yes. The only HRT product a pharmacy can supply without a prescription is Gina 10 microgram vaginal tablets, a pharmacy medicine for women aged 50 and over with vaginal symptoms. Everything else, from oestrogen gel to combined patches, needs a prescriber's decision.

That leaves three models. The first is a pharmacist independent prescriber on your own team, consulting in the pharmacy or by video and prescribing on a private prescription that you dispense. The second is a clinic-plus-pharmacy arrangement: a separate clinic, doctor-led or pharmacist-led, prescribes, and your pharmacy dispenses and delivers. The third is a hybrid, where your prescriber handles reviews and repeat prescribing for a clinic that does the first assessment. Our guide to how online clinics work with dispensing pharmacies sets out the contracts and the records each side must keep.

Regulation follows the model. A pharmacist-led service inside a registered pharmacy answers to the GPhC. A clinic in which doctors provide treatment is carrying out a CQC-regulated activity and needs its own registration. Either way, the prescriber who consults remotely must follow the GPhC's February 2025 guidance on services at a distance. That means a two-way consultation rather than a questionnaire, verification of the medical history, and contact with the GP with consent where the medicine needs monitoring. HRT is not named in that guidance's list of medicines needing extra safeguards, but it is a long-term treatment with a review schedule, so the same logic applies.

Can you supply HRT under a PGD?

Lawfully, in theory; sensibly, no. A patient group direction can cover a licensed prescription-only medicine, and pharmacies already run private services under PGDs for vaccines and travel medicines. A PGD needs the particulars in Schedule 16 to the 2012 Regulations, signatures from a doctor and a pharmacist, and authorisation by a body the Regulations allow. None of that is the obstacle. The obstacle is what NICE says a PGD is for.

The Specialist Pharmacy Service's guidance on when not to use a PGD, dated 1 April 2026, quotes NICE guideline MPG2. Do not use PGDs for managing long-term conditions. Do not use one where the care pathway gives an opportunity for a qualified prescriber to prescribe the medicine safely for the individual. PGDs are also unsuitable where medicines need frequent or complex monitoring. HRT fails all three tests. Regimen choice depends on the woman's uterus, bleeding pattern, risk factors and preferences; the dose changes; and NICE wants a review at three months and then annually. Our comparison of PGDs and independent prescribing explains why titrated, individual treatments belong with a prescriber.

What the service involves and what HRT monitoring requires

A structured assessment, a regimen decision, and a review cycle that does not lapse. NICE guideline NG23, updated in 2024, says women over 45 with typical symptoms do not need blood tests to diagnose the menopause; the diagnosis is clinical. It says HRT is the most effective treatment for vasomotor symptoms and that, for most healthy women under 60 or within ten years of the menopause, the benefits outweigh the risks. Transdermal oestrogen is preferred where oral treatment raises cardiovascular or gastrointestinal concerns.

Two clinical boundaries matter for a pharmacy service. Testosterone is off-label and NICE does not recommend it routinely; NG23 supports it only for persistent low sexual desire despite adequate oestrogen replacement, which is specialist territory for most pharmacy prescribers. And complex cases belong elsewhere. Premature ovarian insufficiency, a history of breast cancer, or symptoms that persist despite adequate treatment should go to a specialist menopause service, and your pathway should say so.

What it costs patients and what it earns

The medicine is cheap on the NHS, so the service has to sell something else. An NHS prescription in England costs £9.90 an item, and the HRT prescription prepayment certificate covers all the HRT items a woman needs for 12 months for £19.80. One in five HRT items was already dispensed against an HRT PPC in 2024/25. A private prescription cannot use the certificate, so a woman moving from NHS to private HRT pays for the medicine as well as the consultation.

That is why the honest pitch is access and time. Prices for private menopause consultations vary by provider and are not collected anywhere official, so we do not quote a market rate. The structure that works is a higher initial fee for a long first consultation, a lower fee for the three-month and annual reviews, and HRT priced transparently. The revenue is in the reviews. A patient who returns twice a year for several years is worth far more than a first prescription, and she only returns if the review is booked before she leaves.

Supply is the operational risk. HRT shortages sent 57,580 items through Serious Shortage Protocols in 2023/24, up from 7,969 the year before, according to NHSBSA figures reported by The Pharmacist. Four protocols for Estradot patches, SSP079 to SSP082, were extended again on 16 April 2026 and now run to 10 July 2026, allowing Evorel or Estraderm MX as alternatives. A private prescriber who writes for a product on protocol creates a substitution conversation you then have to hold. Prescribe what you can obtain, and keep the protocol list next to the formulary.

Fitting the clinic-plus-pharmacy playbook

A menopause service is the clinic-plus-pharmacy model with a slower rhythm. The consultation is longer, the prescribing is individual, and the review cycle is measured in months and years rather than weeks. The compliance points are the ones you already know from other private services, and they are set out in our guide to setting up a private prescription workflow.

The NHS context is worth watching rather than waiting for. Menopause is being added to the NHS Health Check and is a priority in the renewed Women's Health Strategy, and both will generate GP appointments that do not exist. Community pharmacy has no commissioned menopause role in England, and the NHS pharmacy contraception service shows how long a hormonal service takes to move from pilot to national. In the meantime, a private service that sends the GP a clear summary after every consultation is the one GPs will point women towards. That is how private services are carrying community pharmacy in 2026, and menopause is one of the few with demand that grows on its own.

Key takeaways

FAQs